首页 | 本学科首页   官方微博 | 高级检索  
     


Evaluation and Management of Abnormal Uterine Bleeding
Authors:Mary L. Marnach  Shannon K. Laughlin-Tommaso
Affiliation:Division of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN
Abstract:Abnormal uterine bleeding (AUB) is a common condition that leads to increased health care costs and decreased quality of life. A systematic approach to AUB evaluation can simplify management and enhance women’s well-being. Abnormal uterine bleeding describes any variation from normal bleeding patterns in nonpregnant, reproductive-aged women beyond menarche lasting for at least 6 months. Ambiguous and inconsistent use of terminology and definitions to characterize AUB in the past decades necessitated a new, consensus-based approach to nomenclature and AUB evaluation. This led to the International Federation of Gynecology and Obstetrics (FIGO) System 1 in 2007, which standardized nomenclature, set parameters, and defined normal and abnormal bleeding based on the 5th to 95th percentile data from available large-scale epidemiologic studies. FIGO System 1, endorsed by several national and international societies, improved worldwide communication among educators, clinicians, and researchers. FIGO System 2, published in 2011, focused on classifications of AUB etiology into structural and nonstructural entities using the PALM-COEIN (polyp[s], adenomyosis, leiomyoma, malignancy, coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic, and not yet classified) classification system. The PALM-COEIN classification is facilitated by a complete patient history combined with appropriate imaging, histopathologic analysis, or laboratory evaluation to ensure accurate diagnostic and treatment approaches to AUB. Herein we present the systematic evaluation of AUB.
Keywords:AUB  abnormal uterine bleeding  BTB  breakthrough bleeding  EIN  endometrial intraepithelial neoplasia  FIGO  International Federation of Gynecology and Obstetrics  GnRH  gonadotropin receptor hormone  HMB  heavy menstrual bleeding  IUD  intrauterine device  IV  intravenous  LNG IUS  levonorgestrel intrauterine system  MgFUS  magnetic resonance imaging–guided focused ultrasound  MRI  magnetic resonance imaging  NSAID  nonsteroidal anti-inflammatory drug  OCP  oral contraceptive pill  PALM-COEIN  polyp(s), adenomyosis, leiomyoma, malignancy, coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic, and not yet classified  SERM  selective estrogen receptor modulators  SIS  saline infusion sonohysterography  SPRM  selective progesterone receptor modulator  TVUS  transvaginal pelvic ultrasound  UAE  uterine artery embolization  vWF  von Willebrand factor
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号